Valneva's Amsterdam Test: Investor Confidence on Trial

Valneva meets investors after Lyme vaccine trial miss and Chikungunya withdrawal trigger lawsuits and a 42% stock plunge. The firm pivots to international markets as cash reserves provide a buffer.

Valneva's management team faces a critical audience in Amsterdam on Tuesday, meeting institutional investors for the first time since a devastating one-two punch to its pipeline sent shares tumbling and attracted legal scrutiny. The French biotech firm is navigating a perfect storm of clinical setbacks and regulatory withdrawals, with its stock price down roughly 42% over the past month to trade around 2.66 euros.

The immediate pressure stems from two US law firms, Pomerantz LLP and Bronstein, Gewirtz & Grossman, which have launched investigations into potential securities violations. Their probes were triggered by the March 23, 2026, release of Phase 3 data for the Lyme disease vaccine candidate PF-07307405, developed in partnership with Pfizer. The firms are examining whether Valneva and certain executives may have misled investors in the lead-up to the results.

While the vaccine showed a clinically notable 73.2% efficacy against placebo in the VALOR trial, it failed to meet its pre-specified primary endpoint. The statistical miss was attributed to fewer cases of Lyme disease occurring than anticipated. CEO Thomas Lingelbach has framed the path forward with the FDA as a "matter of negotiation," arguing that the totality of clinical evidence combined with the significant unmet medical need should encourage a flexible review. The company and Pfizer maintain their goal of submitting for regulatory approval in the second half of 2026.

Simultaneously, Valneva's other key commercial hope, the Chikungunya vaccine IXCHIQ, has suffered its own major setback. The company voluntarily withdrew its US marketing applications in January 2026 after reports of serious adverse events in older patients, effectively closing off the American market for the foreseeable future. Analysts have since stripped all US revenue for IXCHIQ from their financial models.

In response, Valneva is pivoting its focus internationally. The vaccine recently gained approval in Brazil, where a pilot vaccination campaign with the Instituto Butantan is underway. The company has donated up to half a million doses, with over 12,000 administered to date. While this provides a foothold, it is unlikely to compensate for the lost US opportunity.

Financially, Valneva retains some breathing room. The company holds cash reserves of approximately 110 million euros and has implemented a 21% cost reduction program. Management forecasts full-year 2026 revenues between 155 and 170 million euros, driven by existing product sales. The upcoming first-quarter results on May 7 will reveal the initial financial impact of the US withdrawal and whether current liquidity can cover both ongoing development costs and escalating legal expenses.

Despite the turmoil, key partners and some investors see value. Pfizer remains committed to advancing the Lyme vaccine program. Furthermore, several market participants have used the steep decline as a buying opportunity. Investment bank Jefferies reaffirmed its buy rating with a $15 price target, while institutional investor Frazier Life Sciences recently purchased shares worth $8.24 million.

The Amsterdam conference represents a pivotal moment for Lingelbach and his team to directly address shareholder concerns, reframe the narrative around the VALOR data, and signal Pfizer's ongoing commitment. Their ability to restore credibility will likely dictate the stock's direction in the crucial weeks leading up to the quarterly financial disclosure.